Colorectal cancer hypermethylation targets and their applications

Through the combination of multigene methylation primer probes and kits based on qPCR, the problem of limited sensitivity of colorectal cancer detection is solved, and high sensitivity detection of the methylation status of colorectal oncogenes is achieved, providing early diagnosis and risk assessment The support of the test significantly improves the accuracy and feasibility of the test.

CN118421801BActive Publication Date: 2024-11-22SHENZHEN ACE GENE TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410882844.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-03
Publication Date
2024-11-22
Estimated Expiration
2044-07-03

AI Technical Summary

Technical Problem

Existing colorectal cancer detection methods have problems with limited sensitivity, especially the lack of efficient support for non-invasive and early diagnosis.

Method used

A multigene methylation primer probe combination and kit based on qPCR is developed to detect the methylation status of colorectal cancer-related genes, and combine specific target regions and primer probe sequences to achieve the purpose of multiple genes. High sensitivity and high specificity detection of methylation state.

Benefits of technology

This method achieves high sensitivity and high specificity for detecting the gene methylation status of colorectal cancer in blood and tissue samples, providing support for early diagnosis and risk assessment, significantly improving the accuracy and feasibility of the detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118421801B_ABST
    Figure CN118421801B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biotechnology and relates to colorectal cancer hypermethylation targets and applications thereof. Specifically, the gene targets include one or more of a first target having DNA shown in SEQ ID NO.13, a second target having DNA shown in SEQ ID NO.14, and a third target having DNA shown in SEQ ID NO.15. By detecting the methylation status of the gene targets in the blood, the risk of colorectal cancer can be detected early, providing strong support for early intervention and treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and relates to colorectal cancer hypermethylation targets and applications thereof. Background Art

[0002] Colorectal cancer is a common malignant tumor in the gastrointestinal tract. Its morbidity and mortality are second only to gastric cancer, esophageal cancer and primary liver cancer among malignant tumors of the digestive system. Its incidence is closely related to lifestyle, genetics, colorectal adenoma, etc. The male-to-female ratio is 1.65:1, and the age of onset tends to be aging. Early diagnosis and treatment of colorectal cancer are crucial to improving cure rate and survival rate. At present, the main detection methods of colorectal cancer include colonoscopy, fecal occult blood test, and molecular diagnosis of blood and stool. Among them, colonoscopy is the gold standard for the diagnosis of colorectal cancer, but it has limitations such as low patient compliance and insufficient resources. Although fecal occult blood test is easy to operate, non-invasive, non-invasive and inexpensive, its sensitivity is limited. Therefore, in addition to colonoscopy and fecal occult blood test, there is an urgent need for a non-invasive and highly sensitive detection method as support and supplement.

[0003] Abnormally methylated genes can be found in colon tissues of people with a high susceptibility to colorectal cancer, indicating that abnormal DNA methylation may be one of the earliest molecular events that initiate the process of colorectal cancer. Subsequently, researchers further discovered that abnormal DNA methylation begins in the early stages of colorectal cancer, including two modes: DNA hypomethylation and DNA hypermethylation, both of which are involved in the entire process of colorectal cancer development. A general decrease in the amount of 5-methyl-cytosine in CpG sites can be observed in almost all colorectal cancers and their precancerous lesions. Hypomethylation is observed in non-progressive or progressive adenomas, adenocarcinomas, and metastatic tumors. The degree of hypomethylation increases significantly with the progression of the disease, and genome-wide hypomethylation has also been shown to be an early common event in the occurrence of colorectal cancer and precancerous lesions. Hypermethylation usually occurs in unmethylated CpG islands in gene promoters, especially in the promoter regions of some important tumor suppressor genes (such as CDKN2A, MLH1, and APC); in addition, higher methylation levels were found in advanced cancers compared with precancerous lesions, indicating that gene promoter-specific hypermethylation leads to downregulation of key tumor suppressor gene expression, thereby promoting colorectal cancer. Therefore, lesions can be identified by detecting abnormal methylation levels of sensitive genes, which provides new possibilities for early diagnosis of colorectal cancer.

[0004] As a non-invasive and convenient detection method, blood testing has unique advantages in the detection of colorectal cancer gene methylation. By detecting the methylation status of specific genes in the blood, the risk of colorectal cancer can be detected early, providing strong support for early intervention and treatment. Summary of the invention

[0005] The purpose of the present invention is to develop a primer probe combination and a kit for detecting multi-gene methylation of colorectal cancer based on qPCR, so as to detect the methylation status of multiple colorectal cancer genes in one reaction tube. The present invention has high sensitivity and high specificity in specific applications.

[0006] To achieve the above objectives, the present invention is implemented through the following technical solutions:

[0007] In the first aspect, the present invention provides a gene target for diagnosing colorectal cancer, wherein the gene target includes one or more of a first target having DNA shown in SEQ ID NO.13, a second target having DNA shown in SEQ ID NO.14, and a third target having DNA shown in SEQ ID NO.15, or the gene target includes one or more of the regions shown in chr1: 207669511-207669991, chr22: 26565396-26565555, chr14: 62584037-62584279.

[0008] Preferably, the gene target consists of a first target having DNA shown in SEQ ID NO.13, a second target having DNA shown in SEQ ID NO.14 and a third target having DNA shown in SEQ ID NO.15, or, the gene target is the region shown in chr1: 207669511-207669991, chr22: 26565396-26565555 and chr14: 62584037-62584279.

[0009] On the other hand, the present invention provides the use of a reagent for detecting the methylation degree of a gene target in the preparation of a product for diagnosing colorectal cancer, wherein the gene target includes one or more of a first target having DNA shown in SEQ ID NO.13, a second target having DNA shown in SEQ ID NO.14, and a third target having DNA shown in SEQ ID NO.15, or the gene target includes one or more of the regions shown in chr1: 207669511-207669991, chr22: 26565396-26565555, chr14: 62584037-62584279.

[0010] Preferably, the detection is performed on a sample from a subject.

[0011] Preferably, the sample includes but is not limited to blood, tissue, blood cells, bone marrow, ascites, fine needle biopsy samples, body fluids containing cells, free floating nucleic acids, sputum, saliva, urine, semen, cerebrospinal fluid, peritoneal fluid, pleural fluid, stool, lymph, skin swab, oral swab, nasal swab or lavage.

[0012] Most preferably, the samples are blood and tissue.

[0013] Preferably, the reagent for detecting the methylation degree of the gene target can also be a reagent used in the following methods: whole genome bisulfite sequencing (WGBS), pyrosequencing, bisulfite sequencing, methylation-specific polymerase chain reaction (methylation-specific PCR, Methylation-Specific PCR, MS-PCR), bisulfite-specific polymerase chain reaction, methylation-sensitive restriction endonuclease-PCR / Southern method, combined bisulfite restriction endonuclease method (Combined Bisulfite Restriction Analysis, COBRA), digital polymerase chain reaction, restriction landmark genome scanning, single nucleotide primer extension, CpG island microarray, single nucleotide primer extension SNUPE, methylation profiling, methylation chip, etc.

[0014] In another aspect, the present invention provides a primer-probe composition or kit for diagnosing colorectal cancer, wherein the composition or kit contains at least one of the following primer-probe sets:

[0015] Preferably, the reagent for detecting the methylation degree of the first target includes a first upstream primer, a first downstream primer and a first probe, the sequence of the first upstream primer is shown in SEQ ID NO.1, the sequence of the first downstream primer is shown in SEQ ID NO.2, and the sequence of the first probe is shown in SEQ ID NO.3.

[0016] Preferably, the reagent for detecting the methylation degree of the second target includes a second upstream primer, a second downstream primer and a second probe, the sequence of the second upstream primer is shown in SEQ ID NO.4, the sequence of the second downstream primer is shown in SEQ ID NO.5, and the sequence of the second probe is shown in SEQ ID NO.6.

[0017] Preferably, the reagent for detecting the methylation degree of the third target includes a third upstream primer, a third downstream primer and a third probe, the sequence of the third upstream primer is shown in SEQ ID NO.7, the sequence of the third downstream primer is shown in SEQ ID NO.8, and the sequence of the third probe is shown in SEQ ID NO.9.

[0018] "Primer" or "probe" in the present invention refers to an oligonucleotide comprising a region complementary to a sequence of at least 6 consecutive nucleotides of a target. In some embodiments, the primer or probe comprises a region complementary to a sequence of at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19 or at least 20 consecutive or discontinuous block nucleotides of the target molecule. When the primer or probe comprises a region complementary to at least n consecutive nucleotides of a target molecule, the primer or probe is at least 95% complementary to at least n consecutive nucleotides of the target molecule. In some embodiments, the primer or probe is at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary to the target molecule.

[0019] Preferably, the kit contains:

[0020] 1) a first upstream primer having a sequence as shown in SEQ ID NO.1, a first downstream primer having a sequence as shown in SEQ ID NO.2, and a first probe having a sequence as shown in SEQ ID NO.3,

[0021] 2) a second upstream primer having a sequence as shown in SEQ ID NO.4, a second downstream primer having a sequence as shown in SEQ ID NO.5, and a second probe having a sequence as shown in SEQ ID NO.6, and,

[0022] 3) A third upstream primer having a sequence as shown in SEQ ID NO.7, a third downstream primer having a sequence as shown in SEQ ID NO.8 and a third probe having a sequence as shown in SEQ ID NO.9.

[0023] Preferably, the kit further comprises an internal reference upstream primer, an internal reference downstream primer and an internal reference probe for detecting an internal reference gene.

[0024] More preferably, the internal reference gene is ACTB, the internal reference upstream primer for detecting ACTB has the sequence shown in SEQ ID NO.10, the internal reference downstream primer for detecting ACTB has the sequence shown in SEQ ID NO.11, and the internal reference probe for detecting ACTB has the sequence shown in SEQ ID NO.12.

[0025] More preferably, both ends of the first probe, the second probe, the third probe and the internal reference probe are independently provided with a fluorescent labeling group and a fluorescent quenching group.

[0026] More preferably, the labeling groups and quenching groups at both ends of the first probe, the second probe, the third probe and the internal reference probe may be the same or different, preferably complementary and identical.

[0027] Preferably, the labeling group includes but is not limited to FAM (Carboxy fluorescein), FITC (Fluorescein isothiocyanate), HEX (Hexachloro fluorescein), CY5 (cyanine 5), ROX, TET, JOE, rhodamine, AlexaFluor dyes, ATTO dyes, etc.

[0028] Preferably, the marker group includes FAM, HEX, CY5, and ROX.

[0029] Preferably, the quenching group includes but is not limited to DABCYL, TAMRA, MGB, BHQ-0, BHQ-1, BHQ-2, and BHQ-3.

[0030] Preferably, the quenching group is BHQ1, BHQ2, BHQ3.

[0031] More preferably, the 5' end and 3' end of the first probe have FAM and BHQ1, respectively.

[0032] More preferably, the 5' end and 3' end of the second probe have HEX and BHQ1, respectively.

[0033] More preferably, the 5' end and 3' end of the third probe have ROX and BHQ2, respectively.

[0034] More preferably, the 5' end and 3' end of the internal reference probe have CY5 and BHQ3, respectively.

[0035] Preferably, the kit may also contain reagents required for bisulfite conversion, and the reagents specifically include bisulfite buffer and protective buffer. Wherein, bisulfite is selected from one or more of sodium bisulfite, sodium sulfite, sodium bisulfite, ammonium bisulfite and ammonium sulfite; the protective buffer is composed of an oxygen free radical scavenger, and the oxygen free radical scavenger is selected from one or more of hydroquinone, vitamin E, vitamin E derivatives, gallic acid, Trolox, trihydroxybenzoic acid and trihydroxybenzoic acid derivatives. After the DNA is treated with a bisulfite reagent, its unmethylated cytosine nucleotides will be converted into uracil, while the methylated cytosine and other bases remain unchanged, so it is possible to distinguish between methylated and unmethylated cytidines in, for example, CpG dinucleotide sequences.

[0036] Preferably, the kit may also contain reagents required for DNA extraction.

[0037] Preferably, the kit may also include reagents required for PCR amplification reaction.

[0038] Preferably, the kit may further contain any one or more of the following: a container, instructions for use, a positive control, a negative control, a buffer, an adjuvant or a solvent.

[0039] In another aspect, the present invention provides a colorectal cancer diagnosis system, the diagnosis system comprising: a detection component, and a result judgment component;

[0040] The detection component detects the methylation degree of at least one of the first target, the second target and the third target, or the detection component detects the methylation degree of at least one of the regions shown in chr1: 207669511-207669991, chr22: 26565396-26565555, chr14: 62584037-62584279, the first target has the DNA shown in SEQ ID NO.13, the second target has the DNA shown in SEQ ID NO.14, and the third target has the DNA shown in SEQ ID NO.15.

[0041] Preferably, the result judging component is used to output the diagnosis result of colorectal cancer according to the methylation degree detection result of the detection component. Specifically, the diagnosis result is colorectal cancer or no colorectal cancer.

[0042] More specifically, the result judgment component is used according to the judgment rule that: if 2 or 3 of the 3 methylation targets are detected and CT ≤ threshold (alternatively, 30, 31, 32, 33, 34, 35 or more, preferably 34.26), the sample to be tested is judged to be methylation-positive; if only one or no methylation target is amplified among the 3 methylation targets, the sample to be tested is judged to be methylation-negative.

[0043] The "diagnosis" in the present invention includes the diagnosis of colorectal cancer at any stage, such as early, middle and late stages, and also includes early screening, risk assessment, prognosis, disease identification, judgment of the stage of the disease and selection of therapeutic targets for colorectal cancer.

[0044] In this specification, the term "colorectal" refers to the colon, rectum and / or appendix, that is, the entire large intestine. Therefore, the term "colorectal cancer" includes cancers that occur in the colon, rectum and appendix. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 It is the ROC curve of the three-target combined detection in tissue sample validation.

[0046] Figure 2 It is the ROC curve of the three-target combined detection in blood sample validation.

[0047] Figure 3 This is a typical amplification result graph of a positive quality control product.

[0048] Figure 4 This is a typical amplification result graph of a negative control product.

[0049] Figure 5 This is a typical amplification result diagram of a colorectal cancer positive sample.

[0050] Figure 6 This is a typical amplification result diagram of a healthy person sample. DETAILED DESCRIPTION

[0051] The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes based on the technical solution and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

[0052] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0053] Example 1: Screening of methylation targets by hybridization capture sequencing

[0054] Specific steps:

[0055] Step 1: Library construction

[0056] A total of 115 tissue samples (65 cases of colorectal cancer and 50 partially matched adjacent tissues, all verified by pathology) were collected and the methylation liquid phase capture library was constructed using the Acegen_Human Methylome_2M_Panel_CGI_hg38.bed panel. The genomic samples were quality checked and then subjected to methylation liquid phase capture library construction and sequencing.

[0057] Step 2: Sequencing

[0058] After the library inspection is qualified, different libraries are pooled according to the effective concentration and target data volume requirements and then sequenced by Illumina HiSeq

[0059] Step 3: Bioinformatics Analysis

[0060] After obtaining the original sequencing reads, bioinformatics analysis and screening were performed to obtain the targets and their average methylation levels shown in Table 1. From the average methylation levels counted in Table 1, it can be seen that the average methylation levels of the three targets in colorectal cancer tissue (tCRC) are significantly higher than those in paracancerous tissue (tCRN).

[0061] Table 1. Methylation target related information

[0062]

[0063] Example 2: Tissue Sample Verification

[0064] Specific methylation detection primer probes were designed for multiple methylation sites on the three highly methylated genes screened in Example 1, and detection primer probes and capture probes for each target were designed for the internal reference gene ACTB. The 5' end of all probes carries a corresponding fluorescent labeling group (FAM / HEX / CY5 / ROX), and the 3' end carries a corresponding fluorescent quenching group (BHQ1 / BHQ2 / BHQ3). The specific sequence is shown in Table 2. The underlined area in the target sequence in the table is the matching area of ​​the upstream primer (-F1) and the downstream primer (-R1), and the bold mark is the area matched by the probe (-P1). The lowercase letters in the primer and probe sequences represent the methylation modification area.

[0065] Table 2. Primer probe sequences

[0066]

[0067] The above primers and probes were used to test positive quality control products, negative quality control products, and samples to be tested. The positive quality control product was human methylated standard DNA, the negative quality control product was human non-methylated standard DNA, and the samples to be tested were 314 tissue samples (230 colorectal cancer positive, 84 normal intestinal epithelial tissue samples, all confirmed by pathology). The specific steps of the test are:

[0068] Step 1: DNA extraction

[0069] DNA extraction from tissue samples was performed using Jifan Bio's nucleic acid extraction reagent (magnetic bead method). For detailed operations, please refer to the product manual.

[0070] Step 2: Bisulfite conversion

[0071] The bisulfite conversion was performed using the EZ-96 DNA Methylation-LightningTM Ma-gPrep Kit from ZYMO RESEARCH. The specific steps are as follows:

[0072] ①Preparation before the experiment: prepare the magnetic beads used for desulfurization purification (prepare M-Binding Buffer: MagBinding Beads=60:1 by volume, MagBingding is easy to precipitate, so mix thoroughly), 80% ethanol and M-ElutionBuffer (TE).

[0073] ② Add 104 μL Lightining Conversion Reagent (keep away from light and record the date of opening) to 16 μL of DNA sample to be treated with BS, mix thoroughly, and perform the following reaction on a PCR instrument:

[0074] Reaction volume: 120 μL

[0075] Reaction conditions: hot lid 105℃, 98℃, 8min; 54℃, 60min; 4℃, hold (no more than 20h)

[0076] ③ Binding: Add 488 μL (M-Binding Buffer + MagBinding Beads) magnetic beads and gently pipette to mix, let stand for 5 minutes, and then place on the magnetic stand for 2-5 minutes until the solution is completely clear;

[0077] ④ Washing: Use a pipette to slowly discard the supernatant, and avoid disturbing the magnetic beads with the pipette tip. Add 200 μL of freshly prepared 80% ethanol, gently wash the magnetic beads, and discard the supernatant after standing for 30 seconds.

[0078] ⑤ Desulfurization: Add 160 μL L-Desulfurization Buffer, mix thoroughly by pipetting, let stand at room temperature for 15 min, place on a magnetic stand for 3 min, until the solution is clear and translucent (the total time for this step should not exceed 25 min);

[0079] ⑥ Washing: Use a pipette to slowly discard the supernatant, and avoid disturbing the magnetic beads with the pipette tip. Add 200 μL of freshly prepared 80% ethanol, gently wash the magnetic beads, let stand for 30 seconds, and then discard the supernatant (wash twice);

[0080] ⑦ Drying: Place the magnetic beads on a magnetic rack and let them stand at room temperature for 1-5 minutes to dry them. Wait until the alcohol is completely evaporated, there are no obvious droplets on the tube wall, and the magnetic beads are matte and not cracked.

[0081] ⑧ Elution: Remove from the magnetic rack, add 80 μL TE, mix by pipetting and let stand for 3-5 minutes, adsorb on the magnetic rack for 1-3 minutes, and when the solution is clear and transparent, aspirate the DNA solution into a new centrifuge tube.

[0082] Step 3: Establishment of qPCR amplification system

[0083] ① qPCR reaction solution preparation: prepare the volume required for amplification of each component according to Table 3 (if the number of samples is n, prepare n+3 copies), the final concentration of the primer is 200nM~400nM, and the final concentration of the probe is 100nM~200nM. Mix the prepared PCR reaction solution, centrifuge it, and dispense it into PCR reaction tubes, 20μL per tube.

[0084] Table 3. qPCR reaction system

[0085]

[0086] ② Sample addition: Add the prepared DNA sample (5μL) into the PCR reaction tube. The addition of positive quality control and negative quality control is the same as the sample. After adding the sample, cover the centrifuge tube cap, mix well and centrifuge briefly.

[0087] ③Perform qPCR amplification according to the procedure in Table 3.

[0088] Table 4. qPCR reaction procedure

[0089]

[0090] Step 4: Interpretation of test results

[0091] ①Threshold setting: The threshold line is generally automatically generated by the instrument, but can also be adjusted manually.

[0092] ② Determination of the effectiveness of the kit: the internal reference gene of the negative quality control product is amplified and the CT value is ≤33, and the methylation gene detection site is not amplified; the internal reference gene and the methylation gene of the positive quality control product are both amplified and the CT value is ≤33.

[0093] ③ Sample validity determination: The sample is valid when the internal reference ACTB test CT value is ≤35. If the internal reference ACTB test CT value is >35, retest is required. If the retest internal reference CT value is >35, the sample is invalid and needs to be taken again.

[0094] ④ Determination of methylation test results: if 2 or 3 of the 3 methylation targets are detected and CT ≤ 34.26, the sample to be tested is determined to be methylation-positive; if only one of the 3 methylation targets or no methylation target is amplified, the sample to be tested is determined to be methylation-negative.

[0095] Experimental results:

[0096] Figure 1 This is the ROC curve for the combined use of the three targets to determine the disease status. The area under the ROC curve was 0.9832 (95% CI: 0.9711-0.9953, P < 0.0001).

[0097] Table 5 shows the specific test results of the three-target combination for colorectal cancer tissue samples. According to Table 2, it can be calculated that the sensitivity is 84.78% (195 / 230) and the specificity of blood sample detection is 89.29% (75 / 84).

[0098] Table 5. Results of target combined detection

[0099]

[0100] Example 3: Blood sample verification

[0101] Thirty blood samples from patients diagnosed with colorectal cancer and 20 blood samples from healthy subjects were selected to verify that the DNA extraction from the aforementioned blood samples was performed using the QIAamp Circulating Nucleic Acid Kit extraction reagent.

[0102] DNA extraction procedure:

[0103] 1) Add 200 μL of proteinase K to a 50 mL centrifuge tube and add 2 mL of plasma;

[0104] 2) Add 1.6 mL of Buffer ACL and vortex mix for 30 seconds;

[0105] 3) Incubate at 60°C for 30 min;

[0106] 4) After incubation, add 3.6 mL of Buffer ACB, vortex mix for 30 seconds, and incubate on ice for 5 minutes;

[0107] 5) Insert the QIAamp Mini column into the vacuum pump and make sure the other components of the vacuum pump are connected.

[0108] 6) Carefully transfer the mixture from step 4 into the extender of the vacuum pump and turn on the vacuum pump. When all the mixture has passed through the QIAamp Mini column, turn off the vacuum pump.

[0109] 7) Add 600 μL Buffer ACW1 to the QIAamp Mini column, turn on the vacuum pump, and turn off the vacuum pump after filtering.

[0110] 8) Add 600 μL Buffer ACW2 to the QIAamp Mini column, turn on the vacuum pump, and turn off the vacuum pump after filtering;

[0111] 9) Add 750 μL of anhydrous ethanol to the QIAamp Mini column, turn on the vacuum pump, and turn off the vacuum pump after filtering.

[0112] 10) Place the QIAamp Mini column in a clean 2 mL collection tube and centrifuge at 20,000 g for 3 min.

[0113] 11) Place the QIAamp Mini column into a new 2 mL collection tube and incubate at 56°C for 10 min.

[0114] 12) Place the QIAamp Mini column in a new 1.5 mL centrifuge tube, add 50 μL Buffer AVE, and incubate at room temperature for 3 min.

[0115] 13) After incubation, centrifuge at 20,000 g for 1 min to obtain purified nucleic acid.

[0116] Bisulfite conversion was performed according to the protocol described in Example 1, and methylation qPCR detection was performed.

[0117] Experimental results:

[0118] Table 6 shows the results of the combined detection of three targets in blood samples. NoCt in the table indicates no amplification curve. Calculation shows that the sensitivity of the combined detection of three targets of CR1, SEZ6L and LINC00643 genes in blood is 83.33% (25 / 30), the specificity is 95% (19 / 20), and the ROC curve is 0.9717 (95% CI: 0.9327-1, P < 0.0001). The ROC curve is shown in the figure. Figure 2 The qPCR amplification results of positive quality control products, negative quality control products, colorectal cancer positive samples and healthy human samples in the test are shown in the figure below. Figure 3-6 shown.

[0119] Table 6. Results of combined detection of 3 targets in blood samples

[0120]

[0121]

[0122] The results show that the colorectal cancer methylation detection kit provided by the present invention has high detection sensitivity and specificity when detecting gene methylation in colorectal cancer blood samples, and the result interpretation is simple and convenient.

Claims

1. A gene target combination for diagnosing colorectal cancer, the gene target combination consisting of a first target having DNA shown in SEQ ID NO.13, a second target having DNA shown in SEQ ID NO.14, and a third target having DNA shown in SEQ ID NO.15, or the gene target combination is the region shown in chr1: 207669511-207669991, chr22: 26565396-26565555, and chr14: 62584037-62584279, and the methylation detection of the gene target combination is used for diagnosing colorectal cancer.

2. A composition of primers and probes for diagnosing colorectal cancer, the composition containing a reagent for detecting the degree of methylation of a gene target, the gene target consisting of a first target having DNA shown in SEQ ID NO.13, a second target having DNA shown in SEQ ID NO.14, and a third target having DNA shown in SEQ ID NO.15, or the gene target is the region shown in chr1: 207669511-207669991, chr22: 26565396-26565555, and chr14: 62584037-62584279; The reagent for detecting the methylation degree of the first target includes a first upstream primer, a first downstream primer and a first probe, the sequence of the first upstream primer is shown in SEQ ID NO.1, the sequence of the first downstream primer is shown in SEQ ID NO.2, and the sequence of the first probe is shown in SEQ ID NO.3; The reagent for detecting the methylation degree of the second target includes a second upstream primer, a second downstream primer and a second probe, the sequence of the second upstream primer is shown in SEQ ID NO.4, the sequence of the second downstream primer is shown in SEQ ID NO.5, and the sequence of the second probe is shown in SEQ ID NO.6; The reagent for detecting the methylation degree of the third target includes a third upstream primer, a third downstream primer and a third probe, the sequence of the third upstream primer is shown in SEQ ID NO.7, the sequence of the third downstream primer is shown in SEQ ID NO.8, and the sequence of the third probe is shown in SEQ ID NO.

9.

3. The composition according to claim 2, further comprising an internal reference upstream primer, an internal reference downstream primer and an internal reference probe for detecting an internal reference gene.

4. The composition of claim 3, wherein the internal reference gene is ACTB, the internal reference upstream primer for detecting ACTB has a sequence shown in SEQ ID NO.10, the internal reference downstream primer for detecting ACTB has a sequence shown in SEQ ID NO.11, and the internal reference probe for detecting ACTB has a sequence shown in SEQ ID NO.

12.

5. The composition of claim 4, wherein the 5' end and 3' end of the first probe have FAM and BHQ1, respectively, the 5' end and 3' end of the second probe have HEX and BHQ1, respectively, the 5' end and 3' end of the third probe have ROX and BHQ2, respectively, and the 5' end and 3' end of the internal reference probe have CY5 and BHQ3, respectively.

6. A kit for diagnosing colorectal cancer, comprising the composition according to claim 2.

7. Use of the composition according to any one of claims 2 to 5 in the preparation of a colorectal cancer diagnosis kit.